Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences.

The live webcasts and archives of these fireside chats can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Contact:

Investor Relations
[email protected]

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: [email protected]

You May Also Be Interested In

• Kensho and Classiq Partner to Expand Access to Quantum Software in Taiwan
• Proline Range Hoods Supplies 14 Island Range Hoods for High School Teaching Kitchen in Bartlett, Illinois
• STRATEGIC PARTNERSHIP WITH CARESTER FOR OXIDE SEPARATION DEVELOPMENT AND 10-YEAR OFFTAKE AGREEMENT